ketanserin has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oldenburger, A | 1 |
| Birk, G | 1 |
| Schlepütz, M | 1 |
| Broermann, A | 1 |
| Stierstorfer, B | 1 |
| Pullen, SS | 1 |
| Rippmann, JF | 1 |
1 other study available for ketanserin and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Modulation of vascular contraction via soluble guanylate cyclase signaling in a novel ex vivo method using rat precision-cut liver slices.
Topics: Adenosine Triphosphate; Animals; Blood Vessels; Carbon Tetrachloride; Endothelin-1; Ketanserin; Live | 2021 |